Loading
Carcinoma, Non Small Cell Lung / Cisplatin / Pembrolizumab · Phase 3 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 randomized trial comparing pembrolizumab with or without intismeran autogene (V940) in resectable NSCLC with incomplete response to neoadjuvant therapy. The study is actively recruiting and has not yet reported results; no efficacy or safety data are available for evaluation.
Phase 3, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Carcinoma, Non-Small-Cell Lung; age from 18 Years. Intervention: Pembrolizumab + Intismeran autogene. Compared with: Pembrolizumab + Placebo — Active Comparator. n = 680. 241 sites across 31 countries.
This is a Phase 3 randomized trial comparing pembrolizumab with or without intismeran autogene (V940) in resectable NSCLC with incomplete response to neoadjuvant therapy. The study is actively recruiting and has not yet reported results; no efficacy or safety data are available for evaluation.
This is a registry record only; no efficacy or safety results are reported.
Results from this trial will determine whether the addition of intismeran autogene to pembrolizumab improves disease-free survival in this high-risk NSCLC population. Clinicians should await completion and publication of results before considering implementation.
This is an active Phase 3 trial registration with no posted results; the study design is rigorous but outcome data are not yet reported, making evidence assessment impossible.
As stated by the source record.
Quoted from the source exactly as published.
Results from this trial will determine whether the addition of intismeran autogene to pembrolizumab improves disease-free survival in this high-risk NSCLC population. Clinicians should await completion and publication of results before considering implementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06623422). This is a study registration, not published results. Lead sponsor: Merck Sharp & Dohme LLC. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 680 participants (ESTIMATED). Conditions: Carcinoma, Non-Small-Cell Lung. Interventions: BIOLOGICAL: Pembrolizumab; DRUG: Cisplatin; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Gemcitabine; DRUG: Paclitaxel; BIOLOGICAL: Intismeran autogene; OTHER: Placebo. Primary outcome measures: Disease-Free Survival (DFS) , Up to ~97 months. Brief summary: The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.